JP2006506969A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006506969A5 JP2006506969A5 JP2004521702A JP2004521702A JP2006506969A5 JP 2006506969 A5 JP2006506969 A5 JP 2006506969A5 JP 2004521702 A JP2004521702 A JP 2004521702A JP 2004521702 A JP2004521702 A JP 2004521702A JP 2006506969 A5 JP2006506969 A5 JP 2006506969A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- diabetes
- group
- active ingredient
- insulin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229920001184 polypeptide Polymers 0.000 claims 41
- 102000004196 processed proteins & peptides Human genes 0.000 claims 41
- 108090000765 processed proteins & peptides Proteins 0.000 claims 41
- 206010012601 diabetes mellitus Diseases 0.000 claims 27
- 239000008194 pharmaceutical composition Substances 0.000 claims 19
- 239000004480 active ingredient Substances 0.000 claims 17
- 230000001225 therapeutic effect Effects 0.000 claims 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 15
- 208000035475 disorder Diseases 0.000 claims 15
- 239000003814 drug Substances 0.000 claims 13
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 10
- 239000000203 mixture Substances 0.000 claims 7
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 7
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 6
- 229940079593 drug Drugs 0.000 claims 6
- 239000008103 glucose Substances 0.000 claims 6
- 239000008177 pharmaceutical agent Substances 0.000 claims 6
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 claims 5
- 102000004877 Insulin Human genes 0.000 claims 5
- 108090001061 Insulin Proteins 0.000 claims 5
- 229940122199 Insulin secretagogue Drugs 0.000 claims 5
- 229940122355 Insulin sensitizer Drugs 0.000 claims 5
- 229940100389 Sulfonylurea Drugs 0.000 claims 5
- 239000003888 alpha glucosidase inhibitor Substances 0.000 claims 5
- 239000000883 anti-obesity agent Substances 0.000 claims 5
- 229940125710 antiobesity agent Drugs 0.000 claims 5
- 150000001875 compounds Chemical class 0.000 claims 5
- 230000002440 hepatic effect Effects 0.000 claims 5
- 229940125396 insulin Drugs 0.000 claims 5
- BNYHRGTXRPWASY-UHFFFAOYSA-N nonylsulfonylurea Chemical compound CCCCCCCCCS(=O)(=O)NC(N)=O BNYHRGTXRPWASY-UHFFFAOYSA-N 0.000 claims 5
- 230000000580 secretagogue effect Effects 0.000 claims 5
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 claims 5
- 208000011580 syndromic disease Diseases 0.000 claims 5
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims 4
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 claims 4
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 claims 4
- 239000013543 active substance Substances 0.000 claims 4
- 239000000556 agonist Substances 0.000 claims 4
- 239000012634 fragment Substances 0.000 claims 4
- 102000040430 polynucleotide Human genes 0.000 claims 4
- 108091033319 polynucleotide Proteins 0.000 claims 4
- 239000002157 polynucleotide Substances 0.000 claims 4
- 229940124597 therapeutic agent Drugs 0.000 claims 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims 3
- 208000032928 Dyslipidaemia Diseases 0.000 claims 3
- 208000002705 Glucose Intolerance Diseases 0.000 claims 3
- 206010060378 Hyperinsulinaemia Diseases 0.000 claims 3
- 206010056997 Impaired fasting glucose Diseases 0.000 claims 3
- 206010022489 Insulin Resistance Diseases 0.000 claims 3
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 238000009472 formulation Methods 0.000 claims 3
- 201000001421 hyperglycemia Diseases 0.000 claims 3
- 230000003451 hyperinsulinaemic effect Effects 0.000 claims 3
- 201000008980 hyperinsulinism Diseases 0.000 claims 3
- 208000006575 hypertriglyceridemia Diseases 0.000 claims 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims 3
- 201000009104 prediabetes syndrome Diseases 0.000 claims 3
- 230000002265 prevention Effects 0.000 claims 3
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 claims 2
- ILPUOPPYSQEBNJ-UHFFFAOYSA-N 2-methyl-2-phenoxypropanoic acid Chemical class OC(=O)C(C)(C)OC1=CC=CC=C1 ILPUOPPYSQEBNJ-UHFFFAOYSA-N 0.000 claims 2
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 2
- 229940030600 antihypertensive agent Drugs 0.000 claims 2
- 239000002220 antihypertensive agent Substances 0.000 claims 2
- 230000001363 autoimmune Effects 0.000 claims 2
- 239000003613 bile acid Substances 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 229940125753 fibrate Drugs 0.000 claims 2
- 238000001415 gene therapy Methods 0.000 claims 2
- 208000004104 gestational diabetes Diseases 0.000 claims 2
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 229960003512 nicotinic acid Drugs 0.000 claims 2
- 235000001968 nicotinic acid Nutrition 0.000 claims 2
- 239000011664 nicotinic acid Substances 0.000 claims 2
- 238000002360 preparation method Methods 0.000 claims 2
- 230000000069 prophylactic effect Effects 0.000 claims 2
- 208000030090 Acute Disease Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 102000018997 Growth Hormone Human genes 0.000 claims 1
- 108010051696 Growth Hormone Proteins 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 229940126033 PPAR agonist Drugs 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- 206010040070 Septic Shock Diseases 0.000 claims 1
- 206010041349 Somnolence Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 230000036528 appetite Effects 0.000 claims 1
- 235000019789 appetite Nutrition 0.000 claims 1
- 230000023852 carbohydrate metabolic process Effects 0.000 claims 1
- 235000021256 carbohydrate metabolism Nutrition 0.000 claims 1
- 238000004113 cell culture Methods 0.000 claims 1
- 208000037976 chronic inflammation Diseases 0.000 claims 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- 230000019439 energy homeostasis Effects 0.000 claims 1
- 239000003862 glucocorticoid Substances 0.000 claims 1
- 208000037824 growth disorder Diseases 0.000 claims 1
- 239000000122 growth hormone Substances 0.000 claims 1
- 208000026278 immune system disease Diseases 0.000 claims 1
- 230000003914 insulin secretion Effects 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 239000002307 peroxisome proliferator activated receptor agonist Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 208000028591 pheochromocytoma Diseases 0.000 claims 1
- 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 230000003449 preventive effect Effects 0.000 claims 1
- RUOJZAUFBMNUDX-UHFFFAOYSA-N propylene carbonate Chemical compound CC1COC(=O)O1 RUOJZAUFBMNUDX-UHFFFAOYSA-N 0.000 claims 1
- 230000001850 reproductive effect Effects 0.000 claims 1
- 208000023504 respiratory system disease Diseases 0.000 claims 1
- 230000036303 septic shock Effects 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 230000004936 stimulating effect Effects 0.000 claims 1
- 150000003626 triacylglycerols Chemical class 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US39573802P | 2002-07-12 | 2002-07-12 | |
| PCT/US2003/021761 WO2004006839A2 (en) | 2002-07-12 | 2003-07-11 | Pituitary adenylate cyclase activating peptide (pacap) receptor (vpac2) agonists and their pharmacological methods of use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006506969A JP2006506969A (ja) | 2006-03-02 |
| JP2006506969A5 true JP2006506969A5 (https=) | 2006-08-10 |
Family
ID=30115918
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004521702A Pending JP2006506969A (ja) | 2002-07-12 | 2003-07-11 | 下垂体アデニル酸シクラーゼ活性化ペプチド（ｐａｃａｐ）受容体（ｖｐａｃ２）アゴニストおよびそれらの薬理学的使用方法 |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US7378494B2 (https=) |
| EP (1) | EP1578358A2 (https=) |
| JP (1) | JP2006506969A (https=) |
| CN (1) | CN101405298A (https=) |
| AR (1) | AR040548A1 (https=) |
| AU (1) | AU2003267990A1 (https=) |
| BR (1) | BR0312621A (https=) |
| CA (1) | CA2491279A1 (https=) |
| DO (1) | DOP2003000669A (https=) |
| GT (1) | GT200300142A (https=) |
| HN (1) | HN2003000217A (https=) |
| IL (1) | IL165499A (https=) |
| MX (1) | MXPA04012305A (https=) |
| PE (1) | PE20040677A1 (https=) |
| PL (1) | PL377025A1 (https=) |
| RU (1) | RU2360922C2 (https=) |
| TW (1) | TW200409641A (https=) |
| UY (1) | UY27893A1 (https=) |
| WO (1) | WO2004006839A2 (https=) |
| ZA (1) | ZA200501118B (https=) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0301431D0 (sv) * | 2003-05-19 | 2003-05-19 | Dermagen | Novel antimicrobial peptides |
| US8460243B2 (en) | 2003-06-10 | 2013-06-11 | Abbott Diabetes Care Inc. | Glucose measuring module and insulin pump combination |
| US7722536B2 (en) | 2003-07-15 | 2010-05-25 | Abbott Diabetes Care Inc. | Glucose measuring device integrated into a holster for a personal area network device |
| AU2005208911A1 (en) * | 2004-01-27 | 2005-08-11 | Bayer Healthcare Llc | Pituitary adenylate cyclase activating peptide (PACAP) receptor (VPAC2) agonists and their pharmacological methods of use |
| DE602005010578D1 (de) * | 2004-05-21 | 2008-12-04 | Lilly Co Eli | Selektive peptidische agonisten des vpac2-rezeptors |
| CA2567635A1 (en) * | 2004-05-21 | 2005-12-01 | Eli Lilly And Company | Selective vpac2 receptor peptide agonists |
| CA3090413C (en) | 2004-06-04 | 2023-10-10 | Abbott Diabetes Care Inc. | Glucose monitoring and graphical representations in a data management system |
| WO2005123109A2 (en) * | 2004-06-12 | 2005-12-29 | Bayer Pharmaceuticals Corporation | Pegylation of vasoactive intestinal peptide (vip)/pituitary adenylate cyclase activating peptide (pacap) receptor 2 (vpac2) agonists and methods of use |
| EP1781695A1 (en) * | 2004-08-18 | 2007-05-09 | Eli Lilly And Company | Selective vpac2 receptor peptide agonists |
| US20080085860A1 (en) * | 2004-08-18 | 2008-04-10 | Eli Lilly And Company | Selective Vpac2 Receptor Peptide Agonists |
| US20080214440A1 (en) * | 2004-10-08 | 2008-09-04 | Forbes Medi-Tech (Research), Inc. | Vasoactive intestinal polypeptide compositions |
| US20090170775A1 (en) * | 2004-10-08 | 2009-07-02 | Transition Therapeutics, Inc. | Vasoactive intestinal polypeptide compositions |
| AU2005294125A1 (en) | 2004-10-08 | 2006-04-20 | Transition Therapeutics Inc. | Vasoactive intestinal polypeptide pharmaceuticals |
| US20070293429A1 (en) * | 2004-10-08 | 2007-12-20 | Therapei Pharmaceuticals, Inc. | Vasoactive Intestinal Polypeptide Compositions |
| US7595294B2 (en) | 2004-10-08 | 2009-09-29 | Transition Therapeutics, Inc. | Vasoactive intestinal polypeptide pharmaceuticals |
| EP1811960A2 (en) * | 2004-11-19 | 2007-08-01 | Novosom AG | Improvements in or relating to pharmaceutical compositions for local administration |
| DE602005014672D1 (de) * | 2004-12-21 | 2009-07-09 | Lubrizol Ltd | Zusammensetzungen |
| ES2365410T3 (es) * | 2005-04-08 | 2011-10-04 | Amylin Pharmaceuticals, Inc. | Formulaciones farmacéuticas que comprenden péptido de incretina y un disolvente polar aprótico. |
| JP2008539723A (ja) * | 2005-05-06 | 2008-11-20 | バイエル・フアーマシユーチカルズ・コーポレーシヨン | 下垂体アデニル酸シクラーゼ活性化ペプチド（ｐａｃａｐ）受容体（ｖｐａｃ２）アゴニストおよびそれらの薬理学的使用方法 |
| US20080194482A1 (en) * | 2005-08-11 | 2008-08-14 | Jorge Alsina-Fernandez | Selective Apac2 Receptor Peptide Agonists |
| BRPI0617740A2 (pt) * | 2005-10-26 | 2011-08-02 | Lilly Co Eli | agonistas seletivos peptìdicos do receptor vpac2, composição farmacêutica e uso dos referidos agonistas |
| CA2638733A1 (en) * | 2006-02-28 | 2007-09-07 | Eli Lilly And Company | Selective vpac2 receptor peptide agonists |
| EP2011506A1 (en) * | 2007-07-05 | 2009-01-07 | Nestec S.A. | Supplementation of maternal diet |
| ES2616231T3 (es) | 2008-08-21 | 2017-06-12 | Immunogenics Llc | Formulación para administración oral de proteínas |
| US10136845B2 (en) | 2011-02-28 | 2018-11-27 | Abbott Diabetes Care Inc. | Devices, systems, and methods associated with analyte monitoring devices and devices incorporating the same |
| EP3177309B1 (en) * | 2014-08-06 | 2024-10-23 | Vascular Biosciences | Compositions containing a car pharmacophore with selectivity to diseased tissue for the therapy or diagnosis of kidney disease and sepsis |
| CA2982861A1 (en) | 2015-04-16 | 2016-10-20 | Alder Biopharmaceuticals, Inc. | Anti-pacap antibodies and uses thereof |
| EP3426288A4 (en) | 2016-04-15 | 2019-10-30 | Alder Biopharmaceuticals, Inc. | ANTI-PACAP ANTIBODIES AND USES THEREOF |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6972319B1 (en) * | 1999-09-28 | 2005-12-06 | Bayer Pharmaceuticals Corporation | Pituitary adenylate cyclase activating peptide (PACAP)receptor 3 (R3) agonists and their pharmacological methods of use |
-
2003
- 2003-07-11 HN HN2003000217A patent/HN2003000217A/es unknown
- 2003-07-11 EP EP03748938A patent/EP1578358A2/en not_active Withdrawn
- 2003-07-11 UY UY27893A patent/UY27893A1/es not_active Application Discontinuation
- 2003-07-11 WO PCT/US2003/021761 patent/WO2004006839A2/en not_active Ceased
- 2003-07-11 CA CA002491279A patent/CA2491279A1/en not_active Abandoned
- 2003-07-11 GT GT200300142A patent/GT200300142A/es unknown
- 2003-07-11 US US10/618,126 patent/US7378494B2/en not_active Expired - Fee Related
- 2003-07-11 PE PE2003000697A patent/PE20040677A1/es not_active Application Discontinuation
- 2003-07-11 AU AU2003267990A patent/AU2003267990A1/en not_active Abandoned
- 2003-07-11 DO DO2003000669A patent/DOP2003000669A/es unknown
- 2003-07-11 AR AR20030102511A patent/AR040548A1/es unknown
- 2003-07-11 BR BR0312621-8A patent/BR0312621A/pt not_active IP Right Cessation
- 2003-07-11 JP JP2004521702A patent/JP2006506969A/ja active Pending
- 2003-07-11 CN CNA038166445A patent/CN101405298A/zh active Pending
- 2003-07-11 RU RU2005103396/13A patent/RU2360922C2/ru not_active IP Right Cessation
- 2003-07-11 MX MXPA04012305A patent/MXPA04012305A/es unknown
- 2003-07-11 PL PL377025A patent/PL377025A1/pl unknown
- 2003-07-11 TW TW092118986A patent/TW200409641A/zh unknown
-
2004
- 2004-12-01 IL IL165499A patent/IL165499A/en not_active IP Right Cessation
-
2005
- 2005-02-08 ZA ZA200501118A patent/ZA200501118B/en unknown
-
2008
- 2008-05-23 US US12/154,468 patent/US20090258826A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006506969A5 (https=) | ||
| JP7529743B2 (ja) | Ｇｌｐ－１アゴニストとｎ－（８－（２－ヒドロキシベンゾイル）アミノ）カプリル酸の塩とを含む固体組成物 | |
| EP3746111B1 (en) | Solid compositions comprising a glp-1 agonist, a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid and a lubricant | |
| JP5715101B2 (ja) | ピルフェニドンおよび薬学的に受容可能な賦形剤のカプセル処方物 | |
| RU2005103396A (ru) | Агонисты рецептора (vpac2) гипофизарного пептида, активирующего аденилатциклазу (расар), и фармакологические способы их применения | |
| JP2006501820A5 (https=) | ||
| US20180000768A1 (en) | Intestinal fxr agonism enhances glp-1 signaling to restore pancreatic beta cell functions | |
| US11167014B2 (en) | Solid glp-1 derivative compositions for oral administration | |
| TW201206447A (en) | Pharmaceutical formulations | |
| EP3730127A1 (en) | Solid compositions comprising a glp-1 agonist and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid | |
| US11560375B2 (en) | Composition and method for treating metabolic disorders | |
| US20180071277A1 (en) | Oral dosage forms for oxygen-containing active agents and oxyl-containing polymer | |
| CN110251473B (zh) | 羟哌吡酮口服缓释制剂 | |
| CN116785412B (zh) | 一种glp-1类似物口服递送组合物 | |
| WO2025001424A1 (zh) | 具有提高药物口服生物利用度的组合物及其方法 | |
| WO2016066668A1 (en) | Pharmaceutical combinations of vildagliptin and ppar agonists | |
| US20250152527A1 (en) | Therapeutic combinations of colchicine and methods of using same | |
| EP3858354A1 (en) | Synergic pharmaceutical combination of a leukotriene-receptor antagonist and an inverse agonist of histamine h1 | |
| WO2025002076A1 (zh) | 一种mk2抑制剂在制备预防和/或治疗疾病药物中的应用 | |
| CN104649944B (zh) | 一类甲氧苯磺酰肼类gpr119激动剂、制备方法及其用途 | |
| WO2024231312A2 (en) | Combination therapy | |
| US20240082176A1 (en) | Dropropizine in combination with ambroxol in the dosage form of syrup and tablets | |
| TWI238063B (en) | Method of manufacturing oral tablet containing Desloratadine | |
| HK40039302B (en) | Solid compositions comprising a glp-1 agonist and a salt of n-(8-(2-hydroxybenzoyl)amino) caprylic acid | |
| HK40017148B (en) | Solid compositions for oral administration |